Cancer Cachexia Market Size, Share & Trends Analysis Report By Therapeutics (Progestogens, Corticosteroids, Combination Therapy, Other Therapeutics), By Mechanism of Action (Appetite Stimulators, Weight Loss Stabilizers) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Cancer Cachexia Market Size & Growth Analysis

The global cancer cachexia market size was valued at USD 2.76 billion in 2025 and is projected to grow from USD 2.87 billion in 2026 to USD 3.91 billion by 2034, registering a CAGR of 3.95% during the forecast period from 2026 to 2034. North America dominated the cancer cachexia market with a market share of 39.2% in 2025.

Market Segmentation

Therapeutics Insights

The global market is segmented into progestogens, corticosteroids, combination therapy, and other therapeutics. The progestogens segment accounted for the largest market share and is estimated to grow at a CAGR of 4.8% during the forecast period. Progestogens, like Medroxyprogesterone Acetate (MPA) and Megestrol Acetate (MA), are currently considered the best treatment option for cancer cachexia. They are available for the treatment of cancer and AIDS-related cachexia. These drugs were fast-acting, and they were also good antiemetics. Although high doses of these agents may produce adrenal suppression, they do not cause side effects, such as myopathy or peptic ulcer disease, usually seen with corticosteroids. Hence, progestogens hold a significant share in the cancer cachexia market, owing to factors such as the low cost of progestogens and the high efficiency in the treatment of cancer cachexia, which will play a significant role in the progestogens segment to maintain its market position.

Request Customizationto receive a tailored report.

Mechanism of Action Insights

The global cancer cachexia industry is segmented into appetite stimulators and weight loss stabilizers. The appetite stimulators segment accounted for the largest market share and is estimated to grow at a CAGR of 3.9% during the forecast period. Patients with cancer commonly experience appetite reduction and weight loss. In cancer patients, unintentional weight loss and anorexia (lack of appetite or desire to eat) are linked to worsened performance status, responsiveness, tolerance to treatment, survival, and quality of life. Therefore, for individuals who show decreased appetite, increasing the usage of an appetite stimulant may be an option. One of the key drivers of the overall market's growth is the rising incidence of cancer cachexia instances.

Speak to an Analystto discuss market opportunities.

Regional Insights

North America dominated the market and is estimated to register a CAGR of 4% during the forecast period. The dominance of the United States is due to the high prevalence of cancer, the rise in healthcare budgets, and government initiatives to provide treatment options to patients suffering from terminal diseases. According to the Centers for Disease Control and Prevention, between 2010 and 2020, the number of new cancer cases in the United States was expected to increase by about 24% in men to more than 1 million cases/year and by about 21% in women to more than 900,000 cases/year. The increasing incidence of malignant cancers in the country and the increasing cachexia that is well known to be associated with increased mortality and decreased well‐being of patients, are gaining more interest, boosting the market growth in the country.

Unlock Regional Insightsto access country-level data, & regional trends.

Europe Cancer Cachexia Market Trends

Europe is the second-largest region. It is anticipated to reach an expected value of USD 1060 million by 2031, registering a CAGR of 5.1%. According to Santé Publique France and the French national cancer institute, the number of cancer cases increased significantly from 1990 to 2018. In 1990, there were 215,000 cancer cases recorded, which had increased to 382,000 by 2018. Furthermore, there is an increase in new cancer cases by 65% in men and 93% in women. The increasing prevalence of cancer and cancer cachexia is increasing the demand for research on the diseases in the country. According to clinicaltrials.gov, there are eight studies as of January 2021 in the country on cancer cachexia. In collaboration with the French College of General Hospital Pneumologists, Chugai Pharma France conducted a trial to assess the frequency of cachexia and the management of cachexia and associated symptoms in a patient population with non-small cell lung cancer. Therefore, the increasing burden of cancer and thus the risk of cachexia, and the growing number of research studies in the countries boost the market growth.

Asia Pacific Market Trends

Asia Pacific is the third-largest region. In China, the primary market growth factors are the increasing cancer burden and the well-established healthcare infrastructure. According to the 2019 analysis by Rui-Mei Feng et al., released in the Cancer Communications Journal, there were 2.9 million additional cancer deaths and an estimated 4.3 million additional cancer cases in China in 2018. Compared to the United States and the United Kingdom, China has a lower cancer incidence but 30% and 40% higher cancer mortality than the United Kingdom and the United States. According to Rui-Mei Feng, in an article published in 2019, 40% of the risk factors for chronic diseases can be attributed to environmental and lifestyle factors in China and other developed countries. Tobacco smoking is the most critical carcinogenic risk factor in China, contributing to ~ 24.5% of cancers in males. Hence, considering the abovementioned factors, the market studied is expected to grow in China.

List of Key and Emerging Players in Cancer Cachexia Market